Date post: | 27-Dec-2015 |
Category: |
Documents |
Upload: | christiana-tyler |
View: | 213 times |
Download: | 0 times |
The Sixth RTD Framework Programme 2002-2006
Thematic Priority 1
Life Sciences: Genomics & Biotechnology for Health
http://europa.eu.int/comm/research/fp6/index_en.html
http://www.cordis.lu/fp6/
F P 6 ( m i n u s t h e n u c l e a r r e s e a r c h p a r t )
1 . F o c u s i n g & i n t e g r a t i n g C o m m u n i t y r e s e a r c h
1 . 1 T h e m a t i c p r i o r i t i e s( s e v e n t h e m e s )
1 . 2 A n t i c i p a t i n g S & T n e e d s
2 . S t r u c t u r i n g E R A 3 . S t r e n g t h e n i n g t h e f o u n d a t i o n s o f E R A
T w o s p e c i f i c p r o g r a m m e s : I n t e g r a t i n g a n d S t r e n g t h e n i n g t h e E u r o p e a n R e s e a r c h A r e aS t r u c t u r i n g t h e E u r o p e a n R e s e a r c h A r e a
Focussing and integrating Community research: 7 Thematic priorities
Budget (million € )
1. Life sciences: genomics & biotechnology
for health 2,255
2. Information society technologies 3,625
3. Nanotechnologies & nanosciences…. 1,300
4. Aeronautics & space 1,075
5. Food quality & safety 685
6. Sustainable development, global change
and ecosystems 2,120
7. Citizens and governance…. 225
TP1. Life sciences: genomics & biotechnology for health
Why focus on genomics ?
Sequencing of human genome (and other genomes)
Major opportunity to improve human health
Stimulus for business activity
Needs to transform mass of raw data into useful knowledge
To be competitive with US and Japan, we need to have a coordinated approach at the European level for many topics in genomics.
EU will invest by scientific interest and for avoiding to become a “client”
Integration with other approaches Multidisciplinarity
First call expected 17 December 2002 Deadline 25 March 2003
Thematic priority 1. First call & Work programme
Illustrations only!
focusing on Networks of Excellence and Integrated Projects
TP1. Life sciences: genomics & biotechnology for health
Funding instruments
New (inclusion of new partners during project life-time)
- Networks of Excellence
- Integrated Projects
“Traditional”
- Specific Targeted Research Projects (STREP)
- Co-ordination actions (CA)
- Specific Support Actions (SSA)Also don’t miss other opportunities (including fellowships) across the whole Sixth Framework Programme!
TP1. Life sciences: genomics & biotechnology for health
Total budget for first call: € 513 million,
broken down as follows:
Instrument € (million)
Integrated project or network of excellence 385 – 410
Specific targeted research project or co-ordination action 92 – 121
Specific support actions 8 – 10
TP1. First call: indicative budget
TP1. First call: indicative budget
15% of FP Thematic Priorities budget is for participation of small and medium sized enterprises
(SMEs)
Specific activities
‘Co-operative research’: carried out by research centres for SMEs or by high- tech SMEs in collaboration with research centres and universities
‘Collective research’: carried out by research centres for industrial
associations or industry groupings in entire sectors of industry dominated by SMEs
i. Advanced genomics and its applications for health (€ 1,100 m)
a. Fundamental knowledge and basic tools for functional genomics in all organisms(FP5: Generic Activities, Research into Genomes and diseases of genetic origin)
b. Application of knowledge and technologies in the field of genomics and biotechnology for health(FP5: Key Action 3, The “Cell Factory”
TP1. Life sciences: genomics & biotechnology for health
TP1. Life sciences: genomics & biotechnology for health
ii. Combating major diseases (€ 1,155 m)
a. Applications- oriented genomic approaches to medical knowledge and technologies
(FP5: GA 7-Chronic and degenerative diseases, diabetes, cardiovascular diseases and rare diseases, GA9-Neurosciences, KA6-Ageing population)
b. Combating cancer (FP5: GA7)
c. Confronting the major communicable diseases linked to poverty (AIDS, tuberculosis, malaria)(FP5: KA2 Control of Infectious Diseases)
Expressions of Interest
Report on the analysis of expressions of interest 2002
Thematic priority 1
“Genomics and biotechnology for health”
http://www.cordis.lu/fp6/eoi-analysis.htm
>Potential topics that could be used for first and subsequent calls of FP6>To help potential participants become familiar with the new instruments
TP1. Life sciences: genomics & biotechnology for health
i. Advanced genomics and its applications for health
a. Fundamental knowledge and basic tools for functional genomics in all organisms
to foster basic understanding of genomic information, by developing the knowledge base, tools and resources needed to decipher the function of genes and gene products relevant to human health
TP1. Life sciences: genomics & biotechnology for health
- Gene expression and proteomics- Structural genomics- Comparative genomics and population genetics- Bioinformatics- Multidisciplinary functional genomics approaches to basic biological processes
TP1. Indicative topics/ instruments for first call
Gene expression and proteomics (2 topics in first call) (1 indicative topic for next call(s))
Developing high throughput tools and approaches for monitoring gene expression and protein profiles and for determining protein function and protein interactions
• Development of advanced array technologies (IP/NoE)- for the analysis, with high precision and sensitivity, of large sets of proteins, DNA and RNA and for functional cell arraysTechnology development
TP1. Indicative topics/ instruments for first call
Structural genomics (3) (2)Developing high throughput approaches for determining high-resolution 3-D structures of macromolecules.
• Development of new hardware and software for the implementation of innovative automated technologies at synchrotron sites (IP)
- developing, assembling, standardising and providing highly integrated and automated technological platforms at synchrotron research centres for high throughput structural genomics
Specific and ambitious objectives Infrastructures can be part of IP and NoE
Comparative genomics and population genetics (2) (4)
Developing model organisms and transgenic tools; developing epidemiology tools and standardised genotyping protocols.
• Integrated tools for functional genomics of non- mammalian vertebrate models for human development and disease mechanisms (IP)
- develop and use high throughput tools, technologies and approaches …. for harvesting large data sets on gene functions...
Model organisms: to complement the ‘integrated project’ on mouse functional genomics (funded by the QoL programme in FP5)
TP1. Indicative topics/ instruments for first call
Bioinformatics (1) (2)Developing bioinformatics tools and resources for data storage,
mining and processing; developing computational biology approaches for in silico prediction of gene function and for the simulation of complex
regulatory networks.
• Developing methods and resources in bioinformatics to focus on the annotation of human and other genomes (NoE)
- cooperation between life scientists and bioinformaticians to coordinate … the design and development of new integrated bioinformatics tools and approaches...
Structuring the field - life scientists & bioinformaticians
Spreading excellence
TP1. Indicative topics/ instruments for first call
Multidisciplinary functional genomics approaches to basic biological processes (7) (8)Elucidation of the mechanisms underlying fundamental
cellular processes, to identify the genes involved and to decipher their biological functions in living organisms.
• Integrated comparative and functional genomics approaches for studying the cell cycle (IP/ NoE)
- multidisciplinary functional genomics approaches in different model organisms for elucidating .. Basic mechanisms controlling the cell cycle
Basic knowledge - wide implications in health research
TP1. Indicative topics/ instruments for first call
Multidisciplinary functional genomics approaches to basic biological processes (continued)
• Multidisciplinary approaches of functional genomics to study chronic inflammation processes in human disease (NoE)
- co-ordination of research activities … Specific diseases can be addressed ..but the emphasis should be on basic mechanisms
Basic mechanisms - implications in many diseases
TP1. Indicative topics/ instruments for first call
Research areas - 1st call - STREP/CA/SSA
• transcription activation, signal transduction, intra-cellular communication, the role of non-coding genomic information, mechanisms of integration of genes
• in silico prediction of gene function and simulation of complex regulatory networks
• development of new tools and approaches, including the standardisation of protocols, to facilitate generation of new knowledge in functional and structural genomics
TP1. Indicative topics/ instruments for first call
1. Advanced genomics and its applications to health
b. Applications of knowledge and technologies in the field of genomics and biotechnology for health
• to foster the competitiveness of Europe’s biotechnology industry
• the integration of small and medium sized enterprises (SMEs) in projects is essential
TP1. Indicative topics/ instruments for first call
Technological platforms for developments in the fields of new diagnostic, prevention and therapeutic tools
- New, safer, more effective drugs, pharmacogenomics approaches (4) (3)
- New diagnostics (1) (2)
- New in vitro tests to replace animals (1) (1)
- New preventive and therapeutic tools (e.g. stem cells, immunotherapies) (3) (6)- Innovative post-genomic research with high potential for application (2) (4)
TP1. Indicative topics/ instruments for first call
New, safer, more effective drugs,pharmacogenomics approaches (4)(3)
translation of the knowledge and methods derived from genomics into concrete applications for drug design and development
• Genome-based individualised medicines (NoE)
- structuring of efforts devoted to characterisation of drug targets.. to optimise individual drug selection, dosage and delivery .. to improve the benefit / risk ratio of drugs
Cooperation of research and clinical centres, ethical bodies, regulatory authorities, healthcare providers, pharmaceutical industry
TP1. Indicative topics/ instruments for first call
New diagnostics (1)(2)early diagnosis, monitoring of disease progression and interpretation of in-vivo data
• Non-invasive diagnostics and diagnostic procedures; development of markers for ante- and neo-natal screening (NoE)
- structuring of efforts devoted to development of non- invasive tools for pre-natal diagnosis and the translation of genomics data into diagnostic applications….
Translational research; cooperation of academia, ethical bodies, regulatory authorities, pharmaceutical industry
TP1. Indicative topics/ instruments for first call
New in vitro tests to replace animal experimentation (1)(1)Directive 86/609/EEC regarding the protection of
animals used for experimental and other scientific purposes
• Combination and application of in vitro cell and sensor technologies in the field of animal in vivo toxicology (IP)
- research should focus on in vitro cell-based toxicological and pharmacological tests for screening drug compounds
Technology development
TP1. Indicative topics/ instruments for first call
New preventative and therapeutic tools (3)(6)
integration of different research activities in genetics, fundamental and clinical research and ethics to provide standardised research materials such as stem cell banks, clinical research protocols and novel preventive and therapeutic
instruments at a European level.• New advances in cell-based therapies for the regeneration of connective tissue (IP)
- application of mesenchymal stem cell research, gene transfer and tissue engineering for the treatment of connective tissue diseases….. defining quality and safety standards for tissue regeneration ... leading to new biological implants capable of functional load bearing
Several disciplines involved Industry, regulatory authorities
TP1. Indicative topics/ instruments for first call
Post-genomics with high application potential (2)(4) use cutting edge technologies in a multidisciplinary
approach to address areas of research that will benefit from the developments resulting from genomics
• Plant platforms for immunotherapeutic biomolecule production (IP)
- focus on pharmaceuticals (vaccines, other immunotherapeutics) for which a plant-based production system offers real advantage and potential
Appropriate participation of developing countries Experimental design to minimise ecological impact
TP1. Indicative topics/ instruments for first call
Research areas - 1st call - STREP/CA/SSANew drugs targeting G-protein coupled receptors through pharmacogenomics
Educational schemes utilising interdisciplinary approaches for the integration of pre-clinical and clinical research (e.g. training events, workshops)
Development of novel non-invasive and repeatable diagnostics using bioinformatic tools
New diagnostic tools for prion associated diseases
TP1. Indicative topics/ instruments for first call
Research areas - 1st call - STREP/CA/SSA
Technology foresight meeting on test development, validation and implementation
Workshop on business opportunities in pharmaceutical toxicology
Partnership event on the development and manufacture of toxicology test methods for regulatory testing needs
Forum on the achievements in raising awareness on the use of alternative methods in Candidate Countries
TP1. Indicative topics/ instruments for first call
TP1. Life sciences: genomics & biotechnology for health
ii. Combating major diseases
a. Applications- oriented genomic approaches to medical knowledge and technologies
- Cardiovascular disease, diabetes, rare diseases- Resistance to antibiotics and other drugs
- Brain and combating diseases of the nervous system
- Human development and the ageing process
TP1. Life sciences: genomics & biotechnology for health
ii. Combating major diseases
a. Applications- oriented genomic approaches to
medical knowledge and technologies• to develop improved strategies for the prevention and
management – using also advanced technologies for health - of
human disease and for living and ageing healthily
• integrate a genomic approach through all relevant organisms into
more established medical approaches for investigating disease
and health determinants
• translational research aimed at bringing basic knowledge through
to clinical application
TP1. Indicative topics/ instruments for first call
Cardiovascular, diabetes, rare diseases (6)(4)> Integrating clinical expertise and resources with relevant
model systems and advanced tools in functional genomics ==>> breakthroughs in prevention and disease management
> Pool Europe’s research resources to tackle rare diseases
• Genomics of heart muscle development and disease (NoE)
- durable integration of researchers working on nor-
mal/abnormal development of the heart… translation of new knowledge to the treatment of complications of heart disease (heart failure, arrhythmias)
Child health: congenital cardiovascular malformation
TP1. Indicative topics/ instruments for first call
Resistance to antibiotics and other drugs (2)(4)> Exploitation of knowledge of microbial genomes and host-
pathogen interactions ==>> vaccines, alternative strategies;> Strategies for optimal use of antimicrobials> Support EC network on epidemiological surveillance and
control of communicable diseases.
• Testing anti-viral drug resistance and understanding resistance development (IP or NoE)
- setting up a broad approach towards testing and
following up antiviral drug resistance in human virus infections…. integrate basic, clinical, pharmacological, immunological and virological research
Brain, combating diseases of the nervous system (6)(5)use genome information to understand better brain function, damage, plasticity and repair, learning, memory, cognition in order to gain new insight into mental processes, to combat neurological disorders and diseases, and to improve brain repair
• Human brain tissue research (NoE) - research and studies on genetic and environmental
influences on brain diseases- standardisation of tissue sampling, shared use,
diagnosis, ethical issues, clinical history, genotyping, accessibility and training
Infrastructural aspects, structuring the field Spreading excellence
TP1. Indicative topics/ instruments for first call
Human development and the ageing process (2)(4)Human genome sequence, genomic and postgenomic research applied to understand human development and healthy ageing in order to develop the evidence base for improving public strategies and to promote healthy living and healthy ageing
• Genetic factors of longevity and healthy ageing (IP/NoE)
- to compare health status, family history, different age
and gender groups, genetic background to identify genetic markers and expression profiles for the prediction of … longevity and healthy ageing
Population studies, special expertise and facilities in
Europe
TP1. Indicative topics/ instruments for first call
Research areas - 1st call - STREP/CA/SSA
Rare disorders of plasma membrane transporters for amino-acids, lipids and sugars
Workshop on the structuring of European research activities to more effectively combat drug resistant hospital infections
Specific brain research support actions
Molecular mechanisms of bone homeostasis - prevention or treatment of osteoporosis
TP1. Indicative topics/ instruments for first call
ii. Combating major diseases
b. Combating cancer (6) (8)Establishing facilities for exploitation of research (evidence-based guidelines for good clinical practice and improved public health strategies), supporting clinical research/clinical trials, supporting translational reseach
• Translating basic knowledge of functional onco-genomics into cancer diagnosis and treatment (IP/NoE)
- large-scale analysis to identify signalling pathways, oncogenes, tumour supressor genes
- epigenetic mechanisms and genomic instability- new molecular targets for anticancer drug discovery
Translational research
TP1. Indicative topics/ instruments for first call
c. Confronting the major communicable
diseases linked to poverty (5) (5)Developing candidate interventions, establishing a clinical trials programme, establishing an AIDS Therapy Trials Network
- HIV/AIDS - malaria- tuberculosis
Also: European and Developing Countries Clinical Trials Partnership (EDCTP) - action through Treaty Article 169
TP1. Indicative topics/ instruments for first call
ii. Combating major diseases
Additional SSAs to be supported:Promotion of SME participation Stimulating international co-operation Linking with Candidate Countries Stimulating exploitation: of research results stemming from past and present EU programmesRealising ERA objectives: activities such as pilot initiatives on benchmarking, cartography, networking, the debate on human values and technology options, or the collective management of the knowledge infrastructures of the future, etcEU Strategy for Life Sciences and Biotechnology. Action Plan attached to COM(2002)27Supporting future research policy development
TP1. Indicative topics/ instruments for first call
EC contribution ?
Integrated project
Rough estimate: € 10-15 million - but higher possible
(compare QoL integrated projects in FP5) http://europa.eu.int/comm/research/fp6/pdf/ip_provisions_111102final.pdf
Network of excellence (examples)
100 researchers, 25 PhD students ca € 10.5 million
200 researchers, 50 PhD students ca € 18.5 millionhttp://europa.eu.int/comm/research/fp6/pdf/noe_111102final.pdf
TP1. First call
How many integrated projects/ network of excellence will be funded for the first call in TP1?
53 topics to be published in the call
Budget available for IP or NoE € 385 – 410 million
Therefore, competition between proposals for the same topic, as well as between topics
Some topics may not be funded
TP1. First call
Indicative schedule
First call published : 17 December 2002
First deadline : (25) March 2003
Other tentative deadlines :
November 2003November 2004November 2005
TP1. First call
Other FP6 actions
related to Life Sciences (health)
“ERA-NET”
•Supporting the cooperation and coordination of research activities carried out at national or regional level
•Health of key groups (major diseases, rare diseases,
poverty-related diseases, alternative/non-conventional
medicine)
http://europa.eu.int/comm/research/fp6/era-net.html
http://europa.eu.int/comm/research/fp6/pdf/11385-2_en.pdf
Other FP6 actions
related to Life Sciences (health)
Anticipating science and technology
needs (“Priority 8” - FP5: GA10-11)
>Research responding to health policy requirements:• implementation of the European Social Agenda• public health and consumer protection
>Health determinants, provision of high quality and sustainable health care services (ageing, demographic change)
>Public health issues, including epidemiology for disease prevention
>Impact of environmental issues on health>Handicapped / disabled people
Other FP6 actions
related to Life Sciences (health)
TP2. Information society technologiesbioinformatics; data handling; communication
TP3. Nanotechnologies … nanobiotechnology; clean technologies; nanodevices for drug delivery; biosensors; tissue
regeneration; biomaterials (FP5: Growth and QoL KA3)
TP5. Food quality and safety nutrition; plant and animal biotech; food diseases and allergies; GMO traceability; functional food; pathogenic microorganisms; BSE (FP5: QoL KA1 & 4)
TP6. Sustainable development and global change renewable energies; marine and terrestrial biodiversity and ecosystems (FP5: EESD)
Fundamental genomics: [email protected]
Applied genomics & biotech:
Major diseases: [email protected]
Cancer: [email protected]
Poverty related diseases: [email protected]
Research related to structuring / strengthening ERA: [email protected]
Further Information
TP1. Life sciences: genomics & biotechnology for health